Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching.

EJHaem · 2021 · PMC9175692 · PMID 35846097

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

Results that did not achieve significance and did not qualify per the noninferiority criteria were treated as inconclusive. 3.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.